Discrepancies in prevalence trends for HIV, hepatitis B virus, and hepatitis C virus in Haiphong, Vietnam from 2007 to 2012

Azumi Ishizaki1, Vuong Thi Tran2, Cuong Hung Nguyen2, Tomoaki Tanimoto1, Huyen Thi Thanh Hoang2, Hung Viet Pham1, Chung Thi Thu Phan1, Xiuqiong Bi1, Thuc Van Pham2, Hiroshi Ichimura1*

1 Department of Viral Infection and International Health, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, 2 Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam

* ichimura@med.kanazawa-u.ac.jp

Abstract

We previously reported a significant reduction in the prevalence of human immunodeficiency virus type 1 (HIV) from 2007 to 2012 in people who inject drugs (PWID; 35.9% to 18.5%, \( p < 0.001 \)) and female sex workers (FSW; 23.1% to 9.8%, \( p < 0.05 \)), but not in blood donors (BD) or pregnant women, in Haiphong, Vietnam. Our aim in the present study was to assess trends in the prevalence of infection with hepatitis B and C viruses (HBV and HCV, respectively). We also investigated the coinfection rates of HBV and HCV with HIV in the same groups. Between 2007 and 2012, HBV prevalence was significantly decreased in BD (18.1% vs. 9.0%, \( p = 0.007 \)) and slightly decreased in FSW (11.0% vs. 3.9%, \( p = 0.21 \)), but not in PWID (10.7% vs. 11.1%, \( p = 0.84 \)). HCV prevalence was significantly decreased in PWID (62.1% in 2007 vs. 42.7% in 2008, \( p < 0.0001 \)), but it had rebounded to 58.4% in 2012 (2008 vs. 2012, \( p < 0.0001 \)). HCV prevalence also increased in FSW: 28.6% in 2007 and 2009 vs. 35.3% in 2012; however, this difference was not significant (2007 vs. 2012, \( p = 0.41 \)). Rates of coinfection with HBV and HCV among HIV-infected PWID and FSW did not change significantly during the study period. Our findings suggest that the current harm reduction programs designed to prevent HIV transmission in PWID and FSW may be insufficient to prevent the transmission of hepatitis viruses, particularly HCV, in Haiphong, Vietnam. New approaches, such as the introduction of catch-up HBV vaccination to vulnerable adult populations and the introduction of HCV treatment as prevention, should be considered to reduce morbidity and mortality due to HIV and hepatitis virus coinfection in Vietnam.

Introduction

Hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus type 1 (HIV) share the same modes of transmission. As a consequence, coinfection of HCV and/or HBV with HIV is frequent, particularly in people who inject drugs (PWID) [1].

We previously reported that the prevalence of HIV decreased significantly from 2007 to 2012 in PWID (35.9% vs. 18.5%, \( p < 0.001 \)) and in female sex workers (FSW; 23.1% vs. 9.8%,...
while there was no significant change in the prevalence of HIV in pregnant women (0.5% in 2007 vs. 0.6% in 2009, \( p = 1.00 \)) or blood donors (BD; 2.9% in 2007 vs. 1.0% in 2012, \( p = 0.29 \)) in Haiphong, Northern Vietnam [2–4]. These reductions in HIV prevalence are due to the rapid expansion of combined antiretroviral treatment (cART) coverage in Vietnam, from 11% in 2005 to 28.4% in 2007 and 53.0% in 2012. These reductions were concurrent in this region with the expansion of harm reduction programs to prevent HIV transmission, such as clean needle and syringe programs, condom promotion programs, and methadone maintenance therapy for PWID and FSW [5]. As the mortality of HIV-infected individuals has decreased following the introduction of cART [6], the impacts of liver-related morbidity and mortality, particularly those due to coinfection with HBV and/or HCV, have increased [7, 8]. Thus, it is important to understand the epidemiology of HBV and HCV and to measure rates of coinfection with these viruses and HIV. Therefore, in the current study, we assessed the trends of HBV and HCV prevalence and rates of coinfection of HBV/HCV with HIV in PWID, FSW, pregnant women, and BD between 2007 and 2012 in Haiphong, Vietnam.

**Subjects and methods**

In 2007, we recruited 760 male PWID (mean age ± standard deviation: 34.1 ± 7.5 years), 91 FSW (24.8 ± 6.0 years), 200 pregnant women (30.8 ± 9.3 years), and 210 BD (69 women, 140 men, and one unknown; 31.2 ± 10.3 years) [2, 9, 10]. In 2008, we recruited 302 male PWID (32.5 ± 8.5 years). In 2009, we recruited 63 FSW (30.1 ± 8 years), 166 pregnant women (26.1 ± 5.4 years), and 206 BD (24 women and 182 men, 29.1 ± 8.3 years) [3]. In 2012, we recruited 389 PWID (32.2 ± 6.9 years), 51 FSW (29.8 ± 7.0 years), and 200 BD (39 women and 161 men, 29.7 ± 9.7 years) [4]. All participants resided in Haiphong, Vietnam and were newly recruited to the current study in each of the years listed above. None of the participants had received antiviral treatment for HIV, HBV, or HCV before recruitment. The ethical committees of Hanoi Medical University, Vietnam and Kanazawa University, Japan reviewed and approved the study protocols. We collected plasma samples from all participants after they had provided written informed consent. We tested the samples for anti-HIV antibodies (HIVAb) with DAINA SCREEN HIV 1/2 (Alere Medical Co., Ltd., Tokyo, Japan), HBV surface antigen (HBsAg) with DAINA SCREEN HBsAg II (Abbott Japan, Tokyo, Japan), and HCV core antigen (HCVAg) with ARCHITECT HCV Ag (Abbott Japan, Tokyo, Japan) and/or Lumispot Eiken HCV Antigen (Eiken Chemical, Tokyo, Japan). All of the tests were performed in accordance with the manufacturers’ instructions [2, 4, 9, 10]. Pairwise comparisons between the results obtained at different sampling periods were conducted with chi-squared and Fisher’s exact tests using the SPSS programs (IBMSPSS statistics 19, IBM Corporation, NY, USA). A \( p \) value of <0.05 was considered significant.

**Results**

From 2007 to 2012, the prevalence of HBV decreased significantly in BD, from 18.1% in 2007 to 11.2% in 2009 and 9.0% in 2012 (2007 vs. 2009, \( p = 0.046 \); 2009 vs. 2012, \( p = 0.47 \); 2007 vs. 2012, \( p = 0.007 \)). HBV prevalence decreased slightly but not significantly in FSW, from 11.0% in 2007 to 3.2% in 2009 and 3.9% in 2012 (2007 vs. 2009, \( p = 0.12 \); 2009 vs. 2012, \( p = 1.00 \); 2007 vs. 2012, \( p = 0.21 \)). The prevalence of HBV did not change significantly in PWID, from 10.7% in 2007 to 11.3% in 2008 and 11.1% in 2012 (2007 vs. 2008, \( p = 0.78 \); 2008 vs. 2012, \( p = 0.92 \); 2007 vs. 2012, \( p = 0.84 \)), or in pregnant women, from 12.5% in 2007 to 10.2% in 2009 (\( p = 0.50 \)) (Fig 1).

The prevalence of HCV decreased significantly in PWID, from 62.1% in 2007 to 42.7% in 2008 (\( p < 0.0001 \)). However, it had rebounded in 2012 (58.4%) to a level similar to that of 2007.
In FSW, the prevalence of HCV did not change from 2007 (28.6%) to 2009 (28.6%), but it had slightly increased in 2012 (35.3%), although the difference was not significant (2007 vs. 2009, \( p = 1.00 \); 2009 vs. 2012, \( p = 0.44 \); 2007 vs. 2012, \( p = 0.41 \)). HCV prevalence in BD did not change from 2009 to 2012 (1.0% in both years; 2009 vs. 2012, \( p = 1.00 \)). Data regarding HCV prevalence in pregnant women were only available for 2009, when it was 0.6% (Fig 1).

There were no significant changes in rates of coinfection with HBV and/or HCV and HIV in PWID in 2007 (\( n = 273 \)) and 2012 (\( n = 72 \)). Coinfection rates in 2007 and 2012 were 2.9% and 5.6%, respectively, for HIV/HBV (\( p = 0.47 \)); 81.3% and 83.3%, respectively, for HIV/HCV (\( p = 0.70 \)); and 7.0% and 2.8%, respectively, for HIV/HBV/HCV (\( p = 0.27 \)) (Table 1). Coinfection rates in FSW infected with HIV also did not change significantly between 2007 (\( n = 21 \)) and 2012 (\( n = 5 \)): 4.8% and 0%, respectively, for HIV/HBV (\( p = 1.00 \)) and 71.4% and 80%, respectively, for HIV/HCV (\( p = 1.00 \)). There were no triple infections in FSW throughout the study period (Table 1). Among BD infected with HIV (\( n = 6 \) in 2007 and \( n = 2 \) in 2012), only one individual was coinfected with HCV in 2012. There was no coinfection in HIV-infected pregnant women throughout the period.

Table 1. Trends in rates of coinfection with HBV and/or HCV and HIV in PWID and FSW from 2007 to 2012 in Haiphong, Vietnam.

| Year | PWID | | | FSW | | | |
|------|------|------|------|------|------|------|
| 2007 | 273  | 8.8% | HIV infection only | 23.8% | 38.5% | 20% |
| 2008 | 81   | 16.1%| HIV and HBV coinfection | 4.9% | 4.9% | 0% |
| 2012 | 72   | 8.3% | HIV and HCV coinfection | 5.6% | 4.8% | 0% |
| 2007 | 21   | 81.3%| HIV, HBV, and HCV coinfection | 83.3% | 83.3% | 83.3% |
| 2009 | 13   | 7.0% | | 71.4% | 61.5% | 80% |
| 2012 | 5    | 3.7% | | 2.8% | 2.8% | 2.8% |

There were no significant differences in coinfection rates in any groups throughout the observation period. PWID: people who inject drugs, FSW: female sex workers.
Discussion

To the best of our knowledge, the present study was the first to investigate the trends of HIV, HBV, and HCV prevalence and coinfection rates in Vietnam. Previously, we reported that HIV prevalence decreased significantly in PWID and FSW, whereas it did not change significantly in BD between 2007 and 2012 in Haiphong, northern Vietnam [4]. In the current study, we used the same samples as in our previous study [4] and found that HBV prevalence did not change significantly in PWID during the study period, whereas it decreased sharply (although not significantly) in FSW from 2007 to 2009 ($p = 0.12$) and significantly in BD from 2007 to 2012 ($p < 0.01$). According to the Vietnam AIDS Response Progress Report, condom use in 2012–2013 was 92% in FSW and 41.2% in PWID [5]. In light of this report, the sharp reduction in HBV prevalence in FSW may be due to the consistent and widespread use of condoms in this group. The significant reduction of HBV prevalence in BD may be the consequence of efforts to replace paid and relative blood donations with unpaid volunteer blood donations and to increase the screening of donated blood for HBV [5].

The prevalence of HCV infection in PWID decreased significantly in 2008 compared to 2007 but then rebounded in 2012. In FSW, HCV prevalence did not change from 2007 to 2008 and then slightly increased in 2012. In Vietnam, 97.3% of PWID reported using sterile injecting equipment when they injected drugs last time, whereas only 20% of people who needed the treatment received the methadone maintenance therapy service in 2013 [5]. The clean needle and syringe program and methadone maintenance therapy could reduce the HCV prevalence among PWID [11] as observed from 2007 to 2008 in the current study. However, the HCV prevalence rebounded in 2012 to the level in 2007. This could be because the current harm reduction program has not yet reached to the majority of high-risk populations for HCV acquisition [12, 13] or may be insufficient to change their risky behaviors [14]. Our findings suggest that current approaches to control and prevent HIV infection, such as expansion of harm reduction programs for PWID and FSW, may be insufficient to reduce the prevalence of HCV in Vietnam.

We observed a wide range of coinfection rates with the hepatitis viruses among HIV-infected individuals in the different risk groups included in the current study. This finding is similar to that of previous reports of different risk groups and geographic areas in Vietnam. Previous studies reported the following rates of coinfection with HIV: HCV, 35.4–100%; HBV, 8.4–28%; and HBV/HCV, 0.5–5.6%. However, these previous studies used a different methodology to determine HCV infection; while we measured HCV antigen to confirm current HCV infection, previous studies used anti-HCV antibody, a marker for both past and current infection [15–18].

In high-HBV endemic areas such as Vietnam, the coinfection rates of HIV with HBV reflect the background prevalence of HBV in the general population [8,9,19]. HIV coinfection is associated with higher rates of HBV chronicity after acute infection, a lower rate of HBe antigen clearance, a higher frequency of cirrhosis, and a higher rate of liver-related mortality than infection with HBV alone [20]. Thus, it is important to prevent HBV acquisition in HIV-infected populations to reduce the burden of liver-related mortality due to HIV/HBV coinfection. Nationwide expansion of the expanded immunization program (EPI) on HBV for infants and the effort to enhance HBV vaccine coverage since 2002 have achieved a marked reduction in HBsAg prevalence from 3.64% in 2000 to 1.64% in 2008 among children under 5 years old in Vietnam [21]; however, the EPI has had no impact on adult population, such as those recruited in the current study. Implementation of catch-up HBV vaccination for vulnerable adult populations, such as people infected with HIV, PWID, and FSW, should be considered to reduce morbidity and mortality due to HIV/HBV coinfection [22, 23].
Several studies have shown that treating chronic HCV infection in PWID with new direct-acting antivirals (DAAs) is cost effective because it reduces the main reservoir of ongoing HCV transmission (HCV treatment as prevention) [24–27]. Durier et al. showed that introduction of HCV treatment for PWID could achieve a substantial reduction in HCV transmission and prevalence in Vietnam using a mathematical model [28]. Treatment of HCV in PWID and FSW coinfected with HIV should be considered to reduce HCV prevalence [29]. New comprehensive approaches, such as increased uptake of HCV testing, screening for HCV in people infected with HIV, introduction of HCV treatment as prevention, expansion of harm reduction programs with peer support, and augmented surveillance systems to address the risk factors associated with HCV acquisition, should be implemented to reduce the morbidity and mortality associated with HIV/HCV coinfection [30–32].

In conclusion, our findings suggest that the current harm reduction programs designed to prevent HIV transmission in PWID and FSW may be insufficient to prevent the transmission of hepatitis viruses, particularly HCV, in Haiphong, Vietnam. New approaches, such as the introduction of catch-up HBV vaccination to vulnerable adult populations and the introduction of HCV treatment as prevention, should be considered to reduce morbidity and mortality due to HIV and hepatitis virus coinfection in Vietnam.

Acknowledgments
The authors are grateful to the participants of this study. The authors would like to thank Ms. K. Matsushita, Mrs. R. Kibaya, and Dr. RW. Lihana of the Department of Viral Infection and International Health, Graduate School of Medical Science, Kanazawa University, Japan for their advice.

Author Contributions
Conceptualization: Azumi Ishizaki, Thuc Van Pham, Hiroshi Ichimura.
Data curation: Azumi Ishizaki, Cuong Hung Nguyen, Huyen Thi Thanh Hoang.
Formal analysis: Azumi Ishizaki, Xiuqiong Bi.
Funding acquisition: Thuc Van Pham, Hiroshi Ichimura.
Investigation: Azumi Ishizaki, Vuong Thi Tran, Cuong Hung Nguyen, Tomoaki Tanimoto, Huyen Thi Thanh Hoang, Hung Viet Pham, Chung Thi Thu Phan.
Methodology: Azumi Ishizaki, Hiroshi Ichimura.
Project administration: Azumi Ishizaki, Thuc Van Pham, Hiroshi Ichimura.
Resources: Azumi Ishizaki, Cuong Hung Nguyen, Thuc Van Pham, Hiroshi Ichimura.
Supervision: Thuc Van Pham, Hiroshi Ichimura.
Validation: Tomoaki Tanimoto, Xiuqiong Bi.
Visualization: Azumi Ishizaki.
Writing – original draft: Azumi Ishizaki.
Writing – review & editing: Hiroshi Ichimura.

References
1. Degenhardt L, Charlson F, Stanaway J, Lamney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B.
findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016; 16:1385–1398. https://doi.org/10.1016/S1473-3099(16)30325-5 PMID: 27665254

2. Ishizaki A, Nguyen CH, Pham TV, Nguyen TV, Saioj K, Kageyama S, et al. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses. 2009; 25:175–182. https://doi.org/10.1089/aid.2008.0193 PMID: 19239356

3. Tran VT, Ishizaki A, Nguyen CH, Hoang HT, Pham HV, Bi X, et al. No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in Northern Vietnam. AIDS Res Hum Retroviruses. 2012; 28:1349–1351. https://doi.org/10.1089/aid.2012.0006 PMID: 22264087

4. Pham HV, Ishizaki A, Nguyen CH, Saina M, Hoang HT, Tran VT, et al. Change in the Prevalence of HIV-1 and the Rate of Transmitted Drug-Resistant HIV-1 in Hai Phong, Northern Vietnam. AIDS Res Hum Retroviruses. 2015; 31:757–759. https://doi.org/10.1089/AID.2015.0071 PMID: 25970900

5. Ministry of Health, Socialist Republic of Viet Nam. Vietnam AIDS response report 2014. Following up the 2011 political declaration on HIV AIDS. Reporting period: January 2012—December 2013: National Committee for AIDS, Drug and Prostitution Prevention and control; 2014. Available from: http://files.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2014countries/VNM_narrative_report_2014.pdf.

6. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014; 384:241–248. https://doi.org/10.1016/S0140-6736(14)60604-8 PMID: 25042234

7. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarval K. Increasing burden of liver disease in patients of hepatitis B and blood-borne virus coinfections in Vietnam. PLoS One. 2012; 7:e39027. https://doi.org/10.1371/journal.pone.0039027 PMID: 22720022

8. Tran VT, Ishizaki A, Nguyen CH, Phan CT, Hoang HT, Pham HV, et al. Change in the Prevalence of HBV infection among different HIV-risk groups in Hai Phong, Vietnam. J Med Virol. 2011; 83:399–404. https://doi.org/10.1002/jmv.21978 PMID: 21646859

9. Tanimoto T, Nguyen CH, Ishizaki A, Phan CT, Hoang HT, Nguyen TV, et al. Prevalence of HBV infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses. 2010; 22:1355–1363. https://doi.org/10.1089/aid.2010.0045 PMID: 2072071

10. Palmateer NE, Taylor A, Goldberg DJ, Munro A, Atkinson C, Shepherd SJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One. 2014; 9:e104515. https://doi.org/10.1371/journal.pone.0104515 PMID: 25110927

11. Ye S, Pang L, Wang X, Liu Z. Epidemiological implications of hepatitis C co-infection in South and Southeast Asia. Curr HIV/AIDS Rep. 2014; 11:128–133. https://doi.org/10.1007/s11904-014-0206-z PMID: 24682917

12. Ahmed T, Long TN, Huong PT, Stewart DE. Drug injecting and HIV risk among injecting drug users in Hai Phong, Vietnam: a qualitative analysis. BMC Public Health. 2015; 15:32. https://doi.org/10.1186/s12889-015-1404-3 PMID: 25613300

13. Treloar C, Mao L, Wilson H. Beyond equipment distribution in Needle and Syringe Programmes: an exploratory analysis of blood-borne virus risk and other measures of client need. Harm Reduct J. 2016; 13:18. https://doi.org/10.1186/s12954-016-0107-0 PMID: 27246345

14. Nadol P, O’Connor S, Duong H, Le LV, Thang PH, Tram TH, et al. Findings from integrated behavioral and biologic survey among males who inject drugs (MWID)—Vietnam, 2009–2010: evidence of the need for an integrated response to HIV, hepatitis B virus, and hepatitis C virus. PLoS One. 2015; 10: e0118304. https://doi.org/10.1371/journal.pone.0118304 PMID: 25692469

15. Huy BV, Vernavong K, Kinh NV. HBV and HCV Coinfection among HIV/AIDS Patients in the National Hospital of Tropical Diseases, Vietnam. AIDS Res Treat. 2014; 2014:581021. https://doi.org/10.1155/2014/581021 PMID: 25580287

16. Dunford L, Carr MJ, Dean J, Nguyen LT, Ta TH, Nguyen BT, et al. A multicentre molecular analysis of hepatitis B and blood-borne virus infections in Viet Nam. PLoS One. 2012; 7:e39027. https://doi.org/10.1371/journal.pone.0039027 PMID: 22720022

17. Zhang L, Celentano DD, Le Minh N, Latkin CA, Mehta SH, Frangakis C, et al. Prevalence and correlates of HCV noninfection and HIV and HCV coinfection among persons who inject drugs in Vietnam. Eur J Gastroenterol Hepatol. 2015; 27:550–556. https://doi.org/10.1097/MEG.0000000000000321 PMID: 25769097
19. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007; 7:402–409. https://doi.org/10.1016/S1473-3099(07)70135-4 PMID: 17521593

20. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009; 49:S138–S145. https://doi.org/10.1002/hep.22883 PMID: 19399813

21. Nguyen TH, Vu MH, Nguyen VC, Nguyen LH, Toda K, Nguyen TN, et al. A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination. Vaccine. 2014; 32:217–222. https://doi.org/10.1016/j.vaccine.2013.11.004 PMID: 24284410

22. Pollack TM, Trang IT, Ngo L, Cuong DD, Thuy PT, Colby DJ. Response to hepatitis B vaccination among HIV-infected adults in Vietnam. J Virus Erad. 2016; 2:102–106. PMID: 27482443

23. World Health Organization. Hepatitis B Vaccines. WHO position paper. Geneva: Weekly epidemiological record; 2009;84: 405–420. Available from: http://www.who.int/wer/2009/wer8440.pdf?ua=1.

24. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol. 2016; 65:17–25. https://doi.org/10.1016/j.jhep.2016.02.007 PMID: 26867489

25. van Santen DK, de Vos AS, Matser A, Willemsen SB, Lindenburg K, Kretzschmar ME, et al. Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands. PLoS One. 2016; 11:e0163488. https://doi.org/10.1371/journal.pone.0163488 PMID: 27711200

26. Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol. 2016; 31:872–882. https://doi.org/10.1111/jgh.13223 PMID: 26514998

27. Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015; 10:374–380. https://doi.org/10.1097/COH.0000000000000179 PMID: 26248124

28. Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One. 2012; 7:e34548. https://doi.org/10.1371/journal.pone.0034548 PMID: 22511949

29. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. Clin Infect Dis. 2013; 57:S118–S124. https://doi.org/10.1093/cid/cit326 PMID: 23884059

30. Bruggmann P, Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015; 26:S22–S26. https://doi.org/10.1016/j.drugpo.2014.08.014 PMID: 25245939

31. World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016. Geneva. 2016. http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1

32. Lima VD, Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, et al. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? PLoS One. 2015; 10:e0143836. https://doi.org/10.1371/journal.pone.0143836 PMID: 26633652